Valproic acid as a therapy for adenomyosis: A comparative case series

Reproductive Sciences

Volumn 17, Issue 10, 2010, Pages 904-912

  Liu, Xishi ^a   Yuan, Lei ^a   Guo, Sun Wei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

adenomyosis; dysmenorrhea; efficacy; menorrhagia; uterine size; valproic acid

Indexed keywords

LEVONORGESTREL; VALPROIC ACID;

ADENOMYOSIS; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DYSMENORRHEA; FEMALE; HUMAN; PRIORITY JOURNAL; TINNITUS; TREATMENT DURATION; UTERUS DISEASE;

ADULT; DYSMENORRHEA; ENDOMETRIOSIS; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; ORGAN SIZE; PAIN MEASUREMENT; RANDOM ALLOCATION; UTERUS; VALPROIC ACID;

EID: 77957107478     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719110373807     Document Type: Article

References (35)

1. Farquhar C., Brosens I. Medical and surgical management of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006 ; 20 (4). 603-616.
2. Bergeron C., Amant F., Ferenczy A. Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006 ; 20 (4). 511-521.
3. Grow DR, Filer RB Treatment of adenomyosis with long-term GnRH analogues: a case report. Obstet Gynecol. 1991 ; 78 (3 pt 2). 538-539.
4. Bragheto AM, Caserta N., Bahamondes L., Petta CA Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception. 2007 ; 76 (3). 195-199.
5. Liu X., Guo SW A pilot study on the off-label use of valproic acid to treat adenomyosis. Fertil Steril. 2008 ; 89 (1). 246-250.
6. Nie J., Lu Y., Liu XS, Guo SW. Immunoreactivity of progesterone receptor isoform B (PR-B), nuclear factor-kappaB, and IkappaBalpha in adenomyosis. Fertil Steril. 2009 ; 92 (3). 886-889.
7. Guo SW Epigenetics of endometriosis. Mol Hum Reprod. 2009 ; 15 (10). 587-607.
8. Peric H., Fraser IS The symptomatology of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006 ; 20 (4). 547-555.
9. Gottlicher M., Minucci S., Zhu P., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001 ; 20 (4). 6969-6978.
10. Phiel CJ, Zhang F., Huang EY, Guenther MG, Lazar MA, Klein PS Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001 ; 276 (39). 36734-36741.
11. Tunnicliff G. Actions of sodium valproate on the central nervous system. J Physiol Pharmacol. 1999 ; 50 (3). 347-365.
12. Johannessen CU Mechanisms of action of valproate: a commentatory. Neurochem Int. 2000 ; 37 (2-3). 103-110.
13. Critchley HO, Wang H., Jones RL, et al. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Hum Reprod. 1998 ; 13 (5). 1218-1224.
14. Fong YF, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception. 1999 ; 60 (3). 173-175.
15. American Academy of Pediatrics Committee on Adolescence ; American College of Obstetricians and Gynecologists Committee on Adolescent Health Care, Diaz A., Laufer MR, Breech LL Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics. 2006 ; 118 (5). 2245-2250.
16. Inhaka R., Gentleman RR R: a language for data analysis and graphics. J Comput Graph Statist. 1996 ; 5 (3). 1923-1927.
17. Wood C. Adenomyosis: difficult to diagnose, and difficult to treat. Diagn Ther Endosc. 2001 ; 7 (2). 89-95.
18. Fedele L., Bianchi S., Frontino G. Hormonal treatments for adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2008 ; 22 (2). 333-339.
19. Fedele L., Bianchi S., Raffaelli R., Portuese A., Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril. 1997 ; 68 (3). 426-429.
20. Wentz AC Chapter 9. Dysmenorrhea, premenstrual syndrome and related discorders. In: HW Jones, Wentz AC, Burnett LS, eds. Novak's Textbook of Gynecology. 11th ed. New York, NY: Lippincott Williams & Wilkins; 1988: 240-262.
21. Herbst AL, Ulfelder H., Poskanzer DC Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971 ; 284 (15). 878-881.
22. Wu Y., Guo SW. Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Gynecol Obstet Invest. 2006 ; 62 (4). 193-205.
23. Nebbioso A., Manzo F., Miceli M., et al. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep. 2009 ; 10 (7). 776-782.
24. Wang J., Mahmud SA, Bitterman PB, Huo Y., Slungaard A. Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. J Biol Chem. 2007 ; 282 (39). 28408-28418.
25. Dong XF, Song Q., Li LZ, Zhao CL, Wang LQ Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor. Neuro Endocrinol Lett. 2007 ; 28 (6). 775-780.
26. Lockwood CJ, Krikun G., Hickey M., Huang SJ, Schatz F. Decidualized human endometrial stromal cells mediate hemostasis, angiogenesis, and abnormal uterine bleeding. Reprod Sci. 2009 ; 16 (2). 162-170.
27. Lindstrom TM, Mohan AR, Johnson MR, Bennett PR Histone deacetylase inhibitors exert time-dependent effects on nuclear factor-kappaB but consistently suppress the expression of proinflammatory genes in human myometrial cells. Mol Pharmacol. 2008 ; 74 (1). 109-121.
28. Nie J., Liu XS, Guo SW Immunoreactivity of oxytocin receptor (OTR) and transient receptor potential vanilloid type 1 (TRPV1) and its correlation with dysmenorrhea in adenomyosis. Am J Obstet Gynecol. 2010 ; 202 (4). 346.e1-8.
29. Mehasseb MK, Bell SC, Pringle JH, Habiba MA Uterine adenomyosis is associated with ultrastructural features of altered contractility in the inner myometrium. Fertil Steril. 2010 ; 93 (7). 2130-2136.
30. Moynihan AT, Hehir MP, Sharkey AM, Robson SC, Europe-Finner GN, Morrison JJ Histone deacetylase inhibitors and a functional potent inhibitory effect on human uterine contractility. Am J Obstet Gynecol. 2008 ; 199 (2). 167.e1-7.
31. Bulletti C., DE Ziegler D., Setti PL, Cicinelli E., Polli V., Flamigni C. The patterns of uterine contractility in normal menstruating women: from physiology to pathology. Ann N Y Acad Sci. 2004 ; 1034: 64-83.
32. Matalliotakis IM, Kourtis AI, Panidis DK Adenomyosis. Obstet Gynecol Clin North Am. 2003 ; 30 (1). 63-82, viii.
33. Flück CE, Yaworsky DC, Miller WL Effects of anticonvulsants on human p450c17 (17alpha-hydroxylase/17,20 lyase) and 3beta-hydroxysteroid dehydrogenase type 2. Epilepsia. 2005 ; 46 (3). 444-448.
34. Stephen LJ, Kwan P., Shapiro D., Dominiczak M., Brodie MJ Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia. 2001 ; 42 (8). 1002-1006.
35. McIntyre RS, Mancini DA, McCann S., Srinivasan J., Kennedy SH Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord. 2003 ; 5 (1). 28-35.